Lung cancer is a major cause of death in the United States and there is a clear need for additional and better therapeutic approaches to its treatment. It is clear that there are multiple oncogenotypes that cause lung cancer and that these different genotypes respond differently to currently approved therapeutics. However, the molecular basis of these differences are not understood completely and a systematic approach to identifying most of the functional differences in cells derived from tumors having different oncogenotypes has not been carried out. The work we propose will provide a systematic study of differential sensitivities of cells with different oncogenic mutations to the loss of function of each human gene, revealing pathways that contain novel drug targets. It will be conducted on a scale large enough to distinguish genetic weaknesses that are specific for a single cell line from potential therapeutic targets that are present in all cells sharing the same set of oncogenic genetic changes. In parallel, we will use high-throughput screening to determine if any of a set of 200,000 compounds, including a subset currently approved for use in humans, has therapeutic benefit in one or more subsets of genetically distinct lung cancer. Compounds that have such activity will be tested for activity against human tumors in explant models. This will provide a potential fast-track for novel therapies as well as a method for detecting tumor specific vulnerabilities that are resistant to detection by RNAi strategies. A database of the combined functional genomic and compound screening results will be made available to the public by linking it to caGRID and uploading compound structures and linked biological data to PubChem.

Public Health Relevance

This project will test the hypothesis that cell lines derived from human lung cancers can be used to identify therapeutic targets, and leads for therapeutic drugs, that are shared by tumors that have a similar gene expression signature. The project will produce a large database that can be used by researchers to design patient-specific, individualized therapies for lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
High Impact Research and Research Infrastructure Programs (RC2)
Project #
1RC2CA148225-01
Application #
7855405
Study Section
Special Emphasis Panel (ZCA1-SRLB-R (O9))
Program Officer
Gerhard, Daniela
Project Start
2009-09-29
Project End
2011-08-31
Budget Start
2009-09-29
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$2,105,337
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Biochemistry
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Tagal, Vural; Wei, Shuguang; Zhang, Wei et al. (2017) SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun 8:14098
Kim, Jimi; McMillan, Elizabeth; Kim, Hyun Seok et al. (2016) XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature 538:114-117
Zhong, Rui; Kim, Jimi; Kim, Hyun Seok et al. (2014) Computational detection and suppression of sequence-specific off-target phenotypes from whole genome RNAi screens. Nucleic Acids Res 42:8214-22
Kim, Hyun Seok; Mendiratta, Saurabh; Kim, Jiyeon et al. (2013) Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155:552-66
Hu, Youcai; Potts, Malia B; Colosimo, Dominic et al. (2013) Discoipyrroles A-D: isolation, structure determination, and synthesis of potent migration inhibitors from Bacillus hunanensis. J Am Chem Soc 135:13387-92
Cancer Target Discovery and Development Network; Schreiber, Stuart L; Shamji, Alykhan F et al. (2010) Towards patient-based cancer therapeutics. Nat Biotechnol 28:904-6